Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|MEDI3617||MEDI3617 is an human monoclonal antibody that prevents the binding of angiopoietin 2 to the Tie2 receptor in vitro, and inhibits angiogenesis and tumor growth in vivo (PMID: 22327175, PMID: 29559563).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||not applicable||MEDI3617||Phase I||Actionable||In a Phase I trial, MEDI3617 monotherapy resulted in objective response in 6% (1/17) and stable disease in 30% (5/17) of patients with ovarian cancer, with a median progression-free survival of 1.4 months (PMID: 29559563; NCT01248949).||29559563|
|Unknown unknown||Advanced Solid Tumor||not applicable||MEDI3617||Phase I||Actionable||In a Phase I trial, MEDI3617 monotherapy resulted in no objective response (0/25) and stable disease in 52% (13/25) of patients with advanced solid tumors, with a median progression-free survival of 1.4 months (PMID: 29559563; NCT01248949).||29559563|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01248949||Phase I||Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel||A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors||Completed|
|NCT02141542||Phase I||Tremelimumab MEDI3617||Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma||Active, not recruiting|